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Background: The level of expression of cannabinoid receptor type 2 (CB2R) in healthy and diseased brain has not
been fully elucidated. Therefore, there is a growing interest to assess the regional expression of CB2R in the brain.
Positron emission tomography (PET) is an imaging technique, which allows quantitative monitoring of very low
amounts of radiolabelled compounds in living organisms at high temporal and spatial resolution and, thus, has
been widely used as a diagnostic tool in nuclear medicine. Here, we report on the radiofluorination of N-aryl-
oxadiazolyl-propionamides at two different positions in the lead structure and on the biological evaluation of the
potential of the two tracers [18F]1 and [18F]2 as CB2 receptor PET imaging agents.
Results: High binding affinity and specificity towards CB2 receptors of the lead structure remained unaffected by
the structural changes such as the insertion of the aliphatic and aromatic fluorine in the selected labelling sites of
1 and 2. Aliphatic and aromatic radiofluorinations were optimized, and [18F]1 and [18F]2 were achieved in
radiochemical yields of ≥30% with radiochemical purities of ≥98% and specific activities of 250 to 450 GBq/μmol.
Organ distribution studies in female CD1 mice revealed that both radiotracers cross the blood–brain barrier (BBB)
but undergo strong peripheral metabolism. At 30 min after injection, unmetabolized [18F]1 and [18F]2 accounted for
60% and 2% as well as 68% and 88% of the total activity in the plasma and brain, respectively. The main
radiometabolite of [18F]2 could be identified as the free acid [18F]10, which has no affinity towards the CB1 and CB2
receptors but can cross the BBB.
Conclusions: N-aryl-oxadiazolyl-propionamides can successfully be radiolabelled with 18F at different positions.
Fluorine substitution at these positions did not affect affinity and specificity towards CB2R. Despite a promising
in vitro behavior, a rather rapid peripheral metabolism of [18F]1 and [18F]2 in mice and the generation of brain
permeable radiometabolites hamper the application of these radiotracers in vivo. However, it is expected that future
synthetic modification aiming at a replacement of metabolically susceptible structural elements of [18F]1 and [18F]2
will help to elucidate the potential of this class of compounds for CB2R PET studies.
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[18F]1 (X1 = 18F)
15 (X1 = OTs)
[18F]2 (X2 = 18F)
     13 (X2 = NMe3+I-)
Figure 1 Aliphatic and aromatic radiofluorination of
N-aryl-oxadiazolyl-propionamides.
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Cannabinoid receptors (CBR) belong to the superfamily of
G protein-coupled receptors (GPCR) and are involved in
various physiological processes. Besides the CBR identified
so far, the cannabinoid receptor type 1 (CB1R) [1] and type
2 (CB2R) [2], another GPCR natively interacting with
endogenous cannabinoids (GPR55) has been proposed as
a third type of CBR [3,4]. While the CB1R is primarily
expressed in the central nervous system, the CB2R is pre-
dominantly located in the periphery, especially in tissues
related to the immune system. In pathological conditions,
the up-regulation of CB2R expression is mostly associated
with inflammatory processes [5,6], neuropathic pain [7-9],
Alzheimer’s disease, and amyotrophic lateral sclerosis
(ALS) [10-13]. It has also been shown that the activation
of CB2R is connected with the induction of apoptosis in
several cancer cell lines [14-17]. However, CB2R are also
expressed in healthy brain under physiological conditions
at very low expression levels [18,19]. Therefore, the
non-invasive quantification of CB2R in the brain, pos-
sibly in general by application of highly sensitive im-
aging techniques such as positron emission tomography
(PET), requires the availability of radioligands binding
with high affinity and high specificity towards CB2R
[20]. Apart from the numerous specific pharmaco-
logically relevant ligands of CB2R reported so far
(see [21,22]), only a limited number have been applied for
the development of PET radiotracers for imaging of CB2R
[23-29]. As we reported earlier, the increase of brain up-
take and metabolic stability and decrease of non-specific
binding remained as a challenge for further development
[29]. Even a follow-up study on [11C]AZD1940 in non-
human primate with PET confirmed a relatively low
CNS exposure of this radioligand [28]. Mu et al.
reported on N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,
4-dihydroquinoline-3-carboxamide as a 11C-labelled
PET probe for imaging of CB2R [30]. Although the
study showed a rather low brain uptake, and two blocking
experiments with GW4058233 to demonstrate the specifi-
city of brain uptake were not conclusive, the potential of
the compound for PET imaging of amyotrophic lateral
sclerosis has been proposed.
Further, a whole-body biodistribution and radiation dos-
imetry study of the CB2R ligand [
11C]NE40 has been
performed in healthy subjects [31]. It showed the expected
biodistribution being compatible with lymphoid tissue
(spleen) uptake and an appropriate uptake and kinetics in
the brain. This underscores the potential of this tracer
for application in central and peripheral inflammation
imaging. Despite this considerable progress in CB2R
PET imaging, a suitable ligand [32] radiolabelled with the
advantageous longer-lived isotope 18F is still missing.
Recently, we reported on the synthesis, radiofluorination,
and first biological investigation of the N-aryl-oxadiazolyl-propionamide [18F]2 as a potential radioligand for the PET
imaging of CB2R [29]. Although the initial radiofluorination
approach using a nitro precursor proved to be unsatis-
factory (yields ≤ 3%), the promising biological findings
encouraged us to revise and upgrade the radiosynthesis
of [18F]2 and to perform a more detailed biological
evaluation.
Methods
We describe an improved synthesis of [18F]2 using a
trimethylammonium precursor for the radiolabelling at
the aromatic site of the lead structure (Figure 1, com-
pound 13, X2 = NMe3
+I). In parallel, we explored the
aliphatic radiofluorination at the carbazole N-alkyl
chain (Figure 1, compound 15, X1 = OTs). The labelling
of the lead compound at two different sites opens up
the possibility to investigate the dependence of affinity,
biodistribution and metabolism of these radiotracers on
the site of radiolabelling.
Results and discussion
Synthesis of N-arylamide oxadiazoles: precursors for
radiochemistry and reference compounds
In a previous study, we have described the synthesis of >20
fluorinated N-arylamide oxadiazoles including labelling
precursors for radiochemistry [29]. Here we describe a
modified and improved route to obtain novel derivatives
for high-yield radiochemistry. In brief, treatment of the ni-
triles 3 and 4 with excess of hydroxylamine hydrochloride
under alkaline conditions delivered the (Z)-amidoximes
5 and 6 in 55% and 73% yield together with amides
7 and 8 (Scheme 1), which have been separated by col-
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1. i.  n-BuLi (1.2 eq)
THF, -78 °C, 30 min
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    -78 °C, 1 h, then rt, 24 h
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Scheme 1 Synthesis of the N-aryl-oxadiazolyl-propionamide derivatives 11, 2, and 14. NH2OH-HCl, hydroxylamine hydrochloride; succ anh,
succinic anhydride; DIC, N,N′-diisopropylcarbodiimide; COMU®, (1-Cyano-2-ethoxy-2-oxoethylidenaminooxy) dimethylamino-morpholino-
carbenium hexafluorophosphate.
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clear magnetic resonance (NMR) spectroscopy. Treatment
of the amidoximes 5 and 6 with excess of succinic anhyd-
ride delivered the acids 9 and 10 in a nearly quantitative
manner. The N-aryl-oxadiazolyl-propionamides 11 and 2
were obtained in high yields (85% and 78%) by using
N, N′-diisopropylcarbodiimide (DIC) as coupling re-
agent [33].
For the aromatic radiofluorination, trimethylammonium
iodide has been used as a leaving group. Although methyl
iodide (MeI) has a very high nucleophilicity, the choice
of I− as a counter ion speeds up the displacement of the
trimethylammonium salt in an aromatic ring during
radiofluorination under mild conditions [34], thus lower-
ing the amount of potential formation of non-radioactive
and radioactive by-products. The trimethylammonium salt
13 was synthesized from the nitro derivative 11 by reduc-
tion, reductive methylation with paraformaldehyde and
NaBH4 [35], and quaternization by employing large excess
of MeI (Scheme 2) [36].
The ethanol derivative 14 was synthesized in four
steps and 28% overall yield starting from the commer-
cially available carbazole (23). The synthesis started withdeprotonation of carbazole with n-BuLi, reaction of the
carbazolyl anion with ethylene sulfate, and subsequent
hydrolysis with dilute H2SO4 to afford the hydroxyethyl
derivative 25 (see ‘Experimental’ section). The crystalline
cyclic ethylene sulfate represents a non-toxic but reactive
alternative to the gaseous and toxic oxirane. However,
there are only few examples for the introduction of a
2-hydroxyethyl group using ethylene sulfate. Nitration
of the hydroxyethylcarbazole 25 was performed with
concentrated nitric acid at 5°C to 10°C to give the 3-nitro
carbazole derivative [37] 24 in 54% yield (Scheme 1).
Reduction of the nitrocarbazole 24 with H2 in the pres-
ence of Pd/C provided the primary aromatic amine 26,
which was precipitated as HCl salt. The final coupling
of the carbazolamine 26 with the propionic acid 10 was
induced by COMU® providing the amide 14 (Scheme 1).
The fluoroethyl reference compound 1 was prepared by
treatment of 14 with the fluorinating agent diethylaminodi-
fluorosulfonium tetrafluoroborate (XtalFluor-E®) (Scheme 2).
In order to obtain the precursor for the radiosynthesis,
the alcohol 14 was transformed into the tosylate 15
since the tosyloxy moiety represents a good leaving group













1. SnCl2 (5 eq), EtOH, 2 h, rt
2. PFA (6 eq), H2SO4 (6 eq)
    NaBH4 (6 eq), 18 h, 0 °C to rt












TsCl (2 eq), 4-DMAP (0.3 eq)
  NEt3 (3.6 eq), THF, rt, 48 h 
R = F:
   XtalFluor-E® (1.5 eq), NEt3-3HF









15, R = OTs, 61%
1,   R = F, 20%
Scheme 2 Synthesis of precursors 13 and 15 and reference compound 1. SnCl2, tin(II) chloride; PFA, paraformaldehyde; MeI, methyl iodide;
4-DMAP, 4-dimethylaminopyridine; XtalFluor-E®, diethylaminodifluorosulfonium tetrafluoroborate; NEt3-3HF, triethylamine trihydrofluoride.
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the trimethylammonium salt 18 and reference compound
17 were synthesized. Intermediate 16 was obtained by acid
protection followed by reduction from 9. To synthesize the
reference compound 17, Sandmeyer reaction has been ap-
plied [38]. The use of tetrafluoroborate as fluorinating re-
agent led to the formation of a complex reaction mixture
whereas the use of KF delivered 17 in 40% yields. Alterna-
tively, 17 could also be obtained from 10 (not shown in
Scheme 3, see ‘Experimental’ section) in improved yield.
The trimethylammonium salt 18 was obtained as described
above in 48% over two steps.Scheme 3 Synthesis of the trimethylammonium salt 18 and referenceRadiochemistry
Reaction conditions, purification, and formulation pro-
cedures were optimized to achieve a high radiochemical
yield (RCY) and a high radiochemical purity in a short
synthesis time. Aliphatic and aromatic radiolabellings
were carried out at 82°C in MeCN under no-carrier-
added (NCA) conditions (Scheme 4). High labelling
yields (Figure 2) were obtained using 2 mg of precursor.
For [18F]1, the optimal conversion of the tosylate 15
was achieved after 10 min (53 ± 6%, n = 12). For [18F]2,
a maximum was reached after 10 min (63 ± 5%, n = 7),
along with a steady loss of product (51 ± 6%, 15 min)compound 17.
Scheme 4 Radiosynthesis of [18F]1 and [18F]2. K[18F]F-K2.2.2-carbonate complex (5.6 mg, 15 μmol), 2 mg (15 or 13), MeCN, 82°C, 10 min.
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trimethylammonium salts under prolonged heating
[39]. Altogether, evaluating the current results of label-
ling of [18F]2, a great improvement was obtained by
using the herein described new trimethylammonium
precursor 13 instead of the formerly applied nitro com-
pound 11 (see Scheme 4) where a radiochemical yield
of only 3% has been achieved [29].
Reaction mixtures were separated by isocratic semi-
preparative HPLC, fractions were collected, and the
identities confirmed by spiked analytical HPLC samples
with the respective reference compounds of [18F]1 and
[18F]2 (Figure 3). Final purification was performed by
solid phase extraction (SPE) using Sep-Pack cartridges,
and for biological investigations, the products were for-
mulated in isotonic saline containing 10% EtOH. The
radiotracers were produced with 30% to 35% RCY, high
radiochemical purities (≥98%), and high specific activities
(250 to 450 GBq/μmol, n = 4).Figure 2 Time-yield curves of the aliphatic ([18F]1) and
aromatic ([18F]2) radiolabellings in MeCN up to 20 min.In vitro stability and logD determination
Investigations on the in vitro stability of [18F]1 and [18F]
2 were performed prior to the experimental determin-
ation of logD values. [18F]1 exhibited a slight tendency
to de-fluorinate at 40°C in Tris–HCl, EtOH, 0.9% NaCl,
and Dulbecco’s phosphate buffer with 89%, 93%, 95%,
and 94% of intact tracer after 30 min of incubation and
no further decrease up to 90 min. [18F]2 showed a very
high stability with ≥98% of intact tracer at incubation in
all selected media up to 90 min. Radio-thin-layer chro-
matography (TLC) and radio-HPLC analyses were in
good agreement, and no further radioactive degradation
products were observed.
Regarding the HPLC-based logD determination, differ-
ences were noticed between isocratic and gradient elutions
using the same column. However, as compiled in Table 1,
the logD values using Reprosil-Pur C18 AQ column under
gradient conditions are in good agreement with those
found with Prodigy 5 μm C8 column.
Receptor affinity
The substitution of the ethyl chain of the carbazole moiety
in 2 with a fluorine-ethyl chain in 1 had little effect on tar-
get affinity and specificity as reflected by comparable Ki
values for the CB2R (1, Ki 2.32 ± 2.12 nM; 2, Ki 4.27 ±
3.03 nM) [29]. Based on the data published by Cheng
et al. [40] (JCPDS 42–44), an agonistic profile of 1 and 2
can be assumed. Both compounds possess no affinity to-
wards the CB1R (Ki > 1 μM). By contrast, one major
brain-penetrating metabolite, compound 10, shows almost
no binding towards the CBRs (Ki CB1R > 1 μM, Ki CB2R >
1 μM). In accordance with the ex vivo autoradiographic
studies on [18F]2 in spleen tissue slices [29], compound
[18F]1 targets CB2R in vivo too. The autoradiograms are
shown in Figure S1 of Additional file 1.
Organ distribution of [18F]1 and [18F]2 in mice
The biodistribution of compounds [18F]1 and [18F]2 in
percentage of injected dose per gram (% ID/g) at 5, 30,
Figure 3 High-performance liquid chromatography. Isocratic semi-preparative RP-HPLC chromatograms (left) and the analytical HPLC
chromatograms (right) of the radiotracers spiked with the respective reference compounds. (A) [18F]1 (tR = 35.3 min), eluent: 58% MeCN/10 mM
NH4OAc aq. on a Reprosil Gold C18, 10 μm, 150 × 4.6 mm; flow rate: 2.5 mL/min. (B) [18F]2 (tR = 35.6 min), eluent: 60% MeCN/20 mM NH4OAc
aq. on a Multospher 120 RP-18 AQ, 5 μm, 150 × 10 mm; flow rate: 2.0 mL/min. The precursors for radiolabelling (13 and 15) and compound 20
(see ‘Experimental’ section) were also identified by analytical HPLC on a Multospher 120 RP 18 AQ column, 5 μm, 250 × 4.6 mm; solvents: A: 10%
MeCN/20 mM NH4OAc, B: 90% MeCN/20 mM NH4OAc. Gradient elution(A%): 0 to 10 min, 100%; 10 to 40 min, gradient from 100% to 0%; 40 to
45 min, 0%; 45 to 50 min, 100% at a flow rate of 1 mL/min.
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and 3. For both radiotracers, the highest uptake was
detected at 5 min p.i. in the spleen. Comparable kinetics
were observed in the brain and most other organs such
as the lung, liver, kidney, thymus, and adrenals after ad-
ministration of [18F]1 and [18F]2, respectively. Both
compounds showed a high gastrointestinal excretion asTable 1 Experimental logD coefficients of compounds
1 and 2
Compound Reposil-Pur C18-AQa Prodigy 5 μ C8a
Isocratic Gradient Isocratic
1 4.21 ± 0.32 3.82 ± 0.10 3.86 ± 0.33
2 4.87 ± 0.36 4.35 ± 0.11 4.40 ± 0.35
aExperiments performed with the respective reference compounds (n = 3 to 6).reflected by the constant increase of activity uptake in
the small intestine. A constantly low uptake of activity
in the femur indicates no confounding defluorination
during the experiment.
The highest accumulation of activity was found in the
kidneys and liver for both compounds. While the activity
uptake is higher in the kidneys for [18F]1, the values for
[18F]2 are higher in the liver, indicating different excre-
tion patterns.
Blocking experiments were performed with pre-
administration of the CB2R-specific inverse agonist
SR144528. At 60 min, the animals were sacrificed and
the percentage of injected dose per gram of activity
uptake was calculated for the various organs. No sig-
nificant reduction of percentage of injected dose per
gram could be observed for both compounds in any of
Table 2 Radioactivity uptake in major organs of female CD1mice after intravenous administration of 300 to 400 kBq
[18F]1
Organ Control (% ID/g) Blocking (% ID/g)
5 mina 30 minb 60 minb 60 minc
Blood 1.94 ± 0.44 1.44 ± 0.41 1.94 ± 0.69 1.43 ± 0.34
Plasma 2.52 ± 0.58 1.88 ± 0.58 2.50 ± 0.87 1.87 ± 0.41
Brain 1.31 ± 0.24 0.76 ± 0.22 0.92 ± 0.27 0.66 ± 0.11
Heart 3.39 ± 0.45 1.43 ± 0.47 1.66 ± 0.37 1.49 ± 0.29
Lung 3.68 ± 0.62 1.65 ± 0.70 1.77 ± 0.74 1.47 ± 0.29
Stomach 2.05 ± 0.33 1.23 ± 0.36 2.70 ± 1.47 1.84 ± 1.28
Small intestine 4.36 ± 2.09 10.51 ± 8.38 22.03 ± 8.32 19.39 ± 5.53
Large intestine 1.91 ± 2.66 3.24 ± 5.61 1.54 ± 0.42 1.63 ± 0.64
Liver 11.00 ± 1.04 4.38 ± 1.19 5.29 ± 1.22 4.22 ± 0.96
Kidney 13.40 ± 5.66 2.68 ± 0.37 1.65 ± 0.49 1.74 ± 0.48
Bladder 2.23 ± 1.39 1.65 ± 0.43 3.27 ± 1.94 5.07 ± 3.84
Spleen 3.44 ± 0.77 1.46 ± 0.56 1.52 ± 0.62 0.98 ± 0.21
Thymus 3.30 ± 0.58 1.57 ± 0.80 1.90 ± 0.98 1.50 ± 0.35
Pancreas 4.97 ± 0.62 1.50 ± 0.74 1.13 ± 0.11 1.03 ± 0.26
Adrenals 4.16 ± 6.23 3.31 ± 0.99 3.16 ± 1.25 3.00 ± 0.64
Gonads 1.06 ± 0.94 1.02 ± 0.26 1.33 ± 0.50 1.19 ± 0.30
Muscle 2.10 ± 0.33 1.02 ± 0.50 0.89 ± 0.19 0.93 ± 0.23
Femur 2.00 ± 0.38 1.37 ± 0.50 1.84 ± 0.35 1.49 ± 0.45
Blocking was performed with pre-administration of SR144528 (3 mg/kg i.p.). Values are mean ± SD. an = 4, bn = 5, cn = 6.
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(details are compiled in Additional file 1: Table S1). For
[18F]2, the pre-administration of SR144528 led to an
increase of percentage of injected dose per gram in some
organs, which might be related to metabolic processes.
Interestingly, major differences between the radioactiv-
ity uptakes in various organs were found for [18F]1 and
[18F]2. Figure 4 shows all organs (plus the blood and liver)
in which significant differences in radioactivity uptake
were found at 60 min after injection of the two radio-
tracers. The measured radioactivity was higher after appli-
cation of [18F]1 in those organs expressing CB2R natively
[18] in comparison to the data obtained after injection of
[18F]2. This relation is reversed in those organs associated
to excretion. The cause of this is probably related to
the much faster metabolism of [18F]2 and its
radiometabolites compared to that of [18F]1, which is in
agreement with the observation of significantly lower
accumulation of radiolabelled compounds in the plasma
and kidney.
The significant differences in the pancreas and femur
can be considered as a further indicator of different meta-
bolic processes of [18F]1 and [18F]2 leading to different
radiometabolites with diverse organ distribution patterns.
Thus, the activity measured in the ex vivo biodistribution
study is largely determined by metabolites bearing
the 18F label.Metabolism of [18F]1 and [18F]2 in mice
Typical HPLC radiochromatograms of brain extracts
are shown in Figure 5. In general, radio-TLC analytics
of plasma, urine, and brain samples obtained at 30 and
60 min p.i. of [18F]1 or [18F]2 are consistent with the
data obtained by radio-HPLC. As shown in Table 4,
unmetabolized [18F]1 accounted for 60% of the recov-
ered activity in plasma samples at 30 min p.i., while 36%
of the total radioactivity can be addressed to a more
hydrophilic metabolite M1a. The amount of intact ra-
diotracer [18F]1 is further reduced at 60 min p.i. to 7%
with a concomitant increase of M1a to 92%.
Radiochromatograms of brain samples at 30 min p.i.
shown in Figure 5 revealed that unmetabolized radio-
tracer corresponded to 68% and 88% of the total activity
after administration of [18F]1 and [18F]2, respectively.
Paralleled by the constantly increasing accumulation of
radiometabolites in the brain, these values decreased to
35% and 43%, respectively, at 60 min p.i. In particular,
these radiometabolites account for 13% (M1a) and 10%
(M2a) as well as 8% (M1b) and 3% (M2b) of total activity
at 30 min p.i. of [18F]1 and [18F]2, respectively, with
the main radiometabolites M1a and M1b reaching
values of 58% and 51% at 60 min p.i., respectively. The
radiometabolite M2a of [
18F]1 corresponds most likely
to the amine, which is formed by enzymatic hydrolysis
of the amide bond in the compound.
Table 3 Radioactivity uptake in major organs of female CD1 mice after intravenous administration of 300 to 400 kBq
[18F]2
Organ Control (%ID/g) Blocking (%ID/g)
5 mina 30 minb 60 mina 60 mina
Blood 2.29 ± 0.48 3.42 ± 0.39 2.50 ± 0.42 3.40 ± 0.21
Plasma 3.87 ± 0.90 6.82 ± 1.19 5.22 ± 0.73 5.78 ± 0.07
Brain 0.62 ± 0.22 0.86 ± 0.34 0.26 ± 0.07 0.28 ± 0.03
Heart 3.42 ± 0.57 2.32 ± 0.24 1.45 ± 0.20 1.53 ± 0.13
Lung 4.62 ± 0.21 3.36 ± 0.02 2.52 ± 0.60 2.31 ± 0.19
Stomach 1.57 ± 1.18 2.09 ± 0.81 2.21 ± 0.43 3.24 ± 2.10
Small intestine 3.86 ± 2.64 20.78 ± 3.28 27.31 ± 2.44 29.64 ± 5.10
Large intestine 0.46 ± 0.06 1.25 ± 0.30 1.86 ± 0.36 1.78 ± 0.23
Liver 31.31 ± 9.91 8.84 ± 0.83 6.27 ± 0.68 10.51 ± 1.10
Kidney 5.86 ± 0.96 5.90 ± 0.15 3.96 ± 1.25 4.91 ± 1.51
Bladder 1.01 ± 0.29 2.02 ± 0.39 1.45 ± 0.57 1.77 ± 0.16
Spleen 10.42 ± 7.67 1.34 ± 0.10 0.68 ± 0.11 0.74 ± 0.10
Thymus 2.30 ± 1.06 1.96 ± 0.22 1.04 ± 0.08 1.77 ± 0.14
Pancreas 2.04 ± 0.59 1.71 ± 0.15 0.82 ± 0.21 1.02 ± 0.11
Adrenals 7.67 ± 2.18 5.38 ± 0.61 2.44 ± 0.72 3.34 ± 0.15
Gonads 1.14 ± 0.32 2.08 ± 0.03 2.29 ± 0.57 1.97 ± 0.39
Muscle 1.00 ± 0.30 0.92 ± 0.15 0.70 ± 0.27 0.70 ± 0.06
Femur 1.63 ± 0.93 1.10 ± 0.03 0.58 ± 0.11 0.61 ± 0.09
Blocking was performed with pre-administration of SR144528 (3 mg/kg i.p.). Values are mean ± SD. an = 3, bn = 2.
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plasma at particular times p.i. also depends on the kin-
etics of the excretion of radiotracer/radiometabolites.
For [18F]2, this is more pronounced than for [18F]1
with unmetabolized [18F]2 accounting for only 2% of
the total radioactivity in the plasma at 30 min p.i. AtFigure 4 Distribution of radioactivity at 60 min in selected
organs after administration of the tracers [18F]1 and [18F]2.
Values are mean ± SD. Significant differences are indicated (*p < 0.05,
**p < 0.01). Plasma, p = 0.0041; kidney, p = 0.0086; brain, p = 0.0070;
pancreas, p = 0.0288; gonads, p = 0.0445; femur, p = 0.0011.this time, more than 90% of the recovered activity in
plasma samples for [18F]2 consisted of the single
radiometabolite M1b. As this value decreases only slightly
up to 60 min p.i. (88%), M1b can be assumed as a rather
metabolically stable compound. This radiometabolite of
[18F]2 probably corresponds to the N-aryl-oxadiazolyl-
propanoic acid resulting from enzymatic hydrolysis of
the amide bond of 2 [40]. To prove this assumption, the
trimethylammonium salt 18 was synthesized as the pre-
cursor of this metabolite. In order introduce 18F into
the molecule, the carbon acid moiety was protected as a
methyl ester resulting in the labelled compound [18F]17
(Scheme 5). It was expected that after injection of this
compound in mice, the ester will be converted into the
free acid [18F]10. Those metabolic pathways are com-
mon for drug inactivation and excretion [41] as well as
for the prodrug concept providing pharmacologically
active metabolites in vivo from pharmacologically
inactive compounds [42]. After intravenous injection
of [18F]17 in CD1 mice, samples of the plasma, brain,
and spleen were analyzed at 30 and 60 min p.i.
(Table 5).
As expected, the methylester [18F]17 (tR = 36 min) is
completely converted to free acid [18F]10 (tR = 22 min)
in the plasma samples already at 30 min p.i. (Scheme 5).
Radio-HPLC analysis of brain samples at 60 min p.i.,
spiked with the reference compounds 2 and 10, confirmed
Figure 5 Analytical radio-HPLC profile of acetonitrile extracts of brain homogenates. (A) At 30 min p.i. and (B) 60 min p.i. Conditions:
Multospher 120 RP 18 AQ, 5 μm, 250 × 4.6 mm. Solvents: A: 10% MeCN/20 mM NH4OAc, B: 90% MeCN/20 mM NH4OAc. Gradient elution (A%): 0
to 10 min, 100%; 10 to 40 min, gradient from 100% to 0%; 40 to 45 min, 0%; 45 to 50 min, 100% at a flow rate of 1 mL/min.
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10 (Figure 6).
Furthermore, in combination with the time-activity data
presented in Table 5, this result indicates that the main
radiometabolite M1b of [
18F]2 derived from peripheral
metabolism ([18F]10) penetrates the blood–brain barrier
(BBB). In addition, analyses of brain and spleen sample
data revealed that no further metabolic transformation of
[18F]10 could be observed up to 60 min p.i. as shown in
Figure 7.
In vitro investigation of the affinity of 10 towards
both hCB2R and hCB1R revealed no specific binding
(Ki > 1 μM). Altogether, these data suggest that non-Table 4 Relative percentages of intact tracer and
radiometabolites in plasma samples
Compound tR (min)
a Plasma
30 min p.i. (%) 60 min p.i. (%)
[18F]1 38.8 60 7
M1a 4.2 36 92
M2a 30.2 3 1
[18F]2 41.7 2 2
M1b 22.9 95 88
M2b 36.4 ≤1 ≤1
At 30 and 60 min p.i. of [18F]1 and [18F]2. aRadio-HPLC (separation conditions,
see ‘Experimental’ section).target binding radiometabolites of [18F]1 and [18F]2 ac-
count for the vast majority of ex vivo activity measured in
the spleen and other organs known to express CB2R. This
corresponds very well with the insignificant displacement
of activity after administration of [18F]1 and [18F]2 by the
CB2R-specific SR144528. Hence, radiometabolites gener-
ated in the periphery penetrate the BBB leading to a pro-
nounced accumulation of the main radiometabolites in
the brain, hampering the application of [18F]1 and [18F]2
for imaging of CB2R in the brain.
Experimental
Materials and general procedures
Unless otherwise noted, moisture-sensitive reactions
were performed under dry nitrogen or argon. All
chemicals and reagents were purchased from commer-
cially available sources and used without further purifi-
cation unless otherwise specified. Tetrahydrofuran
(THF) was dried with sodium/benzophenone and was
freshly distilled before use. For the TLC, silica gel 60
F254 plates (Merck KGaA, Darmstadt, Germany) were
used. For the flash chromatography (fc), silica gel 60,
40 to 64 μm, (Merck) was used. Room temperature (rt)
was 20°C. Melting point was determined using Stuart™
Melting point apparatus SMP3 (Bibby Scientific Ltd,
Staffordshire, UK), uncorrected. Mass spectrometry
(MS) was done using MAT GCQ (Thermo Finnigan
a) b)
Scheme 5 Radiosynthesis and metabolism of [18F]17. (a) Radiolabelling with K[18F]F-K2.2.2-carbonate complex (5.6 mg, 15 μmol), 2 mg of 18,
MeCN, 82°C, 10 min; (b) in vivo metabolism.
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NMR spectra were recorded on VARIAN GEMINI
2000 (200 MHz for 1H NMR, 50 MHz for 13C NMR,
188 MHz for 19F NMR), VARIAN MERCURY plus (300
MHz for 1H NMR, 75 MHz for 13C NMR, 228 MHz for
19F NMR), and VARIAN MERCURY plus and BRUKER
DRX-400 (400 MHz for 1H NMR, 100 MHz for 13C
NMR, 367 MHz for 19F NMR); δ (in ppm)was related
to tetramethylsilane and trichloro-fluoro-methane (CF3Cl),
respectively; coupling constants (J) were given with 0.1-Hz
resolution. Multiplicities of NMR signals are indicated as
follows: s (singlet), d (doublet), t (triplet), m (multiplet), dd
(doublet of doublets), and dt (doublet of triplets). HPLC
method for determination of the product purity was
done with Merck Hitachi Equipment; L-7400 UV de-
tector, L-7200 autosampler, L-7100 pump, and L-7614
degasser were used. The following conditions were used
in the experiment: column, LiChrospher® 60 RP-select
B, 5 μm, 250 × 4.0 mm; flow rate, 1 mL/min; injection
volume, 5.0 μL; detection at λ = 210 nm. Solvents: A:
water with 0.05% (v/v) trifluoroacetic acid, B: MeCN
with 0.05% (v/v) trifluoroacetic acid. Gradient elution
(A%): 0 to 4 min, 90%; 4 to 29 min, gradient from 90%
to 0%; 29 to 31 min, 0%; 31 to 31.5 min, gradient from
0% to 90%; 31.5 to 40 min, 90%.
For radiochemistry, TLC was performed on silica gel
pre-coated plates (Polygram, SIL G/UV254) with petrol-
eum ether/ethyl acetate/ammonia (2:1:0.1, v/v/v), and
the spots were visualized using UV light at 254 nm.
Radio-TLC was recorded using a BAS-1800 II system
Bioimaging Analyzer (Fuji Photo Film, Co. Ltd., Tokyo,
Japan), and images were evaluated with AIDA 2.31 soft-
ware (raytest Isotopenmessgeräte GmbH, Straubenhardt,
Germany). Purification and isolation of the radiotracers
were conducted on a semi-preparative radio-HPLCTable 5 [18F]10 uptake in female CD1mice after
intravenous administration of 100 to 200 kBq [18F]17
Sample 30 min p.i. (% ID/g) 60 min p.i. (% ID/g)
Plasma 18.21 15.38
Brain 0.28 0.29
Spleen 1.35 1.31consisting of a S1021 pump (Sykam GmbH, Eresing,
Germany), UV detector (WellChrom Filter-Photometer
K-2001; Wissenschaftl. Gerätebau Dr. Ing. Herbert
Knauer GmbH, Berlin, Germany), NaI(Tl) counter, and
data acquisition by an automated system (Nina, Nuclear
Interface, GE Medical Systems, Munich, Germany) on a
Reprosil Gold C18, 10 μm, 150 × 4.6 mm, eluent: 58%
MeCN/10 mM NH4OAc aq. at a flow rate of 2.5 mL/min,
and Multospher 120 RP-18 AQ, 5 μm, 150 × 10 mm,
eluent: 60% MeCN/20 mM NH4OAc aq. at a flow rate of
2.0 mL/min, respectively for [18F]1 (tR = 35.3 min) and
[18F]2 (tR = 35.6 min). For the in vivo pharmacokinetic
metabolite evaluation of [18F]17 (tR = 19.5 min) semi-
preparative isolation was performed on a Multospher
120 RP 18 AQ, 5 μm, 150 × 10 mm, eluent: 56% MeCN/
20 mM NH4OAc aq. at a flow rate of 2.0 mL/min. Analyt-
ical chromatographic separations were performed on a
JASCO LC-2000 system (JASCO Labor- und Datentechnik
GmbH, Gross-Umstadt, Germany), incorporating a PU-
2080Plus pump, AS-2055Plus auto injector (100 μL
sample loop) and a UV-2070Plus UV detector (monitor-
ing at 254 nm). All analytical radio-HPLC analyses were
performed using a gradient mode on a Multospher 120
RP18 AQ, 5 μm, 250 × 4.6 m. Solvents: A: 10% MeCN/
20 mM NH4OAc, B: 90% MeCN/20 mM NH4OAc.Gra-
dient elution (A%): 0 to10 min, 100%; 10 to 40 min, gra-
dient from 100% to 0%; 40 to 45 min, 0%; 45 to 50 min,
100% at a flow rate of 1 mL/min.
(Z)-2-Bromo-N′-hydroxy-4-nitrobenzimidamide (5) and
2-bromo-4-nitrobenzamide (7)
To a solution of 2-bromo-4-nitrobenzonitrile 3 (100 mg,
0.44 mmol, 1 eq.) in 5 mL MeOH under argon, Na2CO3
(56 mg, 0.52 mmol, 1.2 eq.) and NH2OH-HCl (76 mg, 1.1
mmol, 2.5 eq.) were added at rt, and the reaction mixture
was refluxed for 15 h. Upon cooling to rt, 10 mL of H2O
was added and the aqueous phase was washed three times
with 10 mL ethyl acetate (EtOAc). The combined organic
extracts were dried over sodium sulfate and filtered. Upon
evaporation of the solvent, column chromatography was
performed (silica, EtOAc/isohexane (IH) 2:8) to give 5 (62
mg, 0.24 mmol, 55%) and 7 (41 mg, 0.17 mmol, 32%) as
colorless solids. 5: 1H NMR (400 MHz, DMSO-d6): δ
Figure 7 In vivo metabolism conversion of [18F]17 to [18F]10. Analytical radio-HPLC profiles of the in vivo metabolism conversion of [18F]17
(tR = 36 min) to [
18F]10 (tR = 22 min, Scheme 5b) in plasma, brain, and spleen samples. (A) At 30 min p.i. and (B) at 60 min p.i. Conditions:
Multospher 120 RP 18 AQ, 5 μm, 250 × 4.6 mm. Solvents: A: 10% MeCN/20 mM NH4OAc, B: 90% MeCN/20 mM NH4OAc.Gradient elution (A%): 0
to 10 min, 100%; 10 to 40 min, gradient from 100% to 0%; 40 to 45 min, 0%; 45 to 50 min, 100% at a flow rate of 1 mL/min.
Figure 6 Analytical radio-HPLC profile of [18F]2 at 60 min p.i spiked with the reference 2 and 10 (M1b). Conditions: Multospher 120 RP 18
AQ, 5 μm, 250 × 4.6 mm. Solvents: A: 10% MeCN/20 mM NH4OAc, B: 90% MeCN/20 mM NH4OAc.Gradient elution (A%): 0 to 10 min, 100%; 10 to
40 min, gradient from 100% to 0%; 40 to 45 min, 0%; 45 to 50 min, 100% at a flow rate of 1 mL/min.
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http://www.orgmedchemlett.com/content/3/1/11(ppm) = 9.70 (s, 1H), 8.41 (d, J = 2.3 Hz, 1H), 8.21 (dd, J =
8.4/2.3 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 5.99 (s, 2H), 5.99
(s, 2H); 13C NMR (100 MHz, DMSO-d6): δ (ppm) = 150.4,
147.8, 141.7, 132.2, 127.3, 122.5, 122.3; MS (ESI+): m/z (%)
= 260/262 (100/100) [M+H]+. 7: 1H NMR (400 MHz,
CDCl3): δ (ppm) = 8.49 (d, J = 2.2 Hz, 1H), 8.24 (dd, J =
8.5, 2.2 Hz, 1H), 7.79 (d, J = 8.5 Hz, 1H); 13C NMR (100
MHz, CDCl3): δ (ppm) = 164.0, 130.6, 128.7, 122.7, 120.0;
MS (ESI+): m/z (%) = 245/247 (100/100) [M+H]+.
(Z)-2-Bromo-4-fluoro-N′-hydroxybenzimidamide (6) and
2-bromo-4-fluorobenzamide (8)
Compounds 6 and 8 (pale yellow solids) were obtained
under the same synthetic procedure described for com-
pounds 5 and 7 with 2-bromo-1-fluoro-4-nitrobenzene
4 as starting reagent. 6 (yield 73%): 1H NMR (400 MHz,
CDCl3): δ (ppm) = 7.46 (dd, J = 8.6, 6.0 Hz, 1H), 7.35
(dd, J = 8.2, 2.5 Hz, 1H), 7.07 (dt, J = 8.1, 4.4 Hz, 1H);
13C NMR (100 MHz, CDCl3): δ (ppm) = 161.7, 151.8,
132.6 (d, J = 8.8 Hz), 120.7 (d, J = 24.7 Hz), 115.1 (d, J =
19.1 Hz), 114.9 (d, J = 19.0 Hz); 19F NMR (376 MHz,
CDCl3): δ (ppm) = −109.3 (dd, J = 14.1, 7.9 Hz); MS (ESI+):
m/z (%) = 233/235 (100/100) [M+H]+. 8 (yield 5%): 1H
NMR (400 MHz, CDCl3): δ (ppm) = 7.49 (dd, J = 8.6, 5.9
Hz, 1H), 7.27 (dd, J = 8.4, 2.3 Hz, 1H), 7.00 (td, J = 8.2, 2.4
Hz, 1H), 3.44 (s, 2H); 13C NMR (100 MHz, CDCl3): δ
(ppm) = 169.7 (d, J = 5.6 Hz), 164.2, 161.7, 133.2, 130.9
(d, J = 9.0 Hz), 120.7 (d, J = 24.7 Hz), 119.9 (d, J = 9.8 Hz),





damide 5 (100 mg, 0.38 mmol, 1 eq.) was dissolved in 1 mL
of dimethylformamide (DMF) under inert atmosphere.
Succinic anhydride (95 mg, 0.95 mmol, 2.5 eq.) and KF
(6.7 mg, 0.11 mmol, 0.3 eq.) were added, and the reaction
mixture was warmed up to 130°C for 30 min. Upon
cooling, 20 mL of H2O was added and the solid was col-
lected by filtration, washed with H2O, and dried to give 9
as a colorless solid (123 mg, 0.36 mmol, 95%) with a melt-
ing point (mp) = 127°C. 1H NMR (400 MHz, DMSO-d6):
δ (ppm) = 8.57 (d, J = 2.3 Hz, 1H), 8.36 (dd, J = 8.6, 2.3
Hz, 1H), 8.07 (d, J = 8.6 Hz, 1H), 3.23 (t, J = 6.9 Hz, 2H),
2.83 (t, J = 6.9 Hz, 2H); 13C NMR (100 MHz, DMSO-d6):
δ (ppm) = 178.8, 173.2, 166.0, 148.4, 133.4, 132.3, 128.5,




Compound 10 (colorless solid) was obtained under the
same synthetic procedure described for compound 9with (Z)-2-bromo-4-fluoro-N′-hydroxybenzen-1-carbo-
ximidamide 6 as starting reagent (yield 95%, mp = 104°C).
1H NMR (400 MHz, DMSO-d6): δ (ppm) = 7.86 (dd, J =
8.7, 6.1 Hz, 1H), 7.82 (dd, J = 8.6, 2.6 Hz, 1H), 7.50 to 7.41
(m, 1H), 3.20 (t, J = 6.9 Hz, 2H), 2.81 (t, J = 6.9 Hz, 2H);
13C NMR (100 MHz, DMSO-d6): δ (ppm) = 179.2, 172.7,
164.1, 161.6, 133.6 (d, J = 9.4 Hz), 124.3 (d, J = 3.5 Hz),
122.1 (d, J = 10.1 Hz), 121.4 (d, J = 25.1 Hz), 115.5 (d, J =




To a solution of acid 9 (50 mg, 0.14 mmol, 1 eq.) and
9-ethyl-9H-carbazol-3-amine 12 (30.9 mg, 0.14 mmol, 1 eq.)
in 5 mL dichloromethane (DCM), N,N′-diisopropylcar-
bodiimide (45 μL, 0.21 mmol, 1.5 eq.) was added at 0°C,
and the reaction was stirred at rt until 9 and 12 were not
visible by TLC control (silica, EtOAc/IH 1:1) (2 h). The
reaction was diluted with 5 mL of DCM and washed
once with 10 mL 0.5 M aq. HCl, 10 mL 0.5 N aq. NaOH
and 10 mL aq. NaCl saturated solution. The organic
phase was dried over sodium sulfate and filtered. Evap-
oration of the solvent afforded a brown solid which was
recrystallized from THF to give 11 (63 mg, 0.11 mmol,
85%) as a white solid. 1H NMR (400 MHz, CDCl3): δ
(ppm) = 8.57 (d, J = 2.0 Hz, 1H), 8.36 to 8.14 (m, 2H),
8.03 (d, J = 8 Hz, 2H), 7.62 to 7.13 (m, 4H), 4.35 (q, J = 7.3
Hz, 2H), 3.49 (t, J = 7.4 Hz, 2H), 3.04 (t, J = 7.4 Hz, 2H),




To a solution of oxadiazole 11 (30 mg, 0.05 mmol, 1 eq.)
and SnCl2-2H2O (63 mg, 0.28 mmol, 5 eq.) in 2 mL of
EtOH, concentrated aq. HCl (37%) was added at rt. Upon
completion (TLC, silica, EtOAc/IH 1:1), 10 mL of satu-
rated aq. NaHCO3 solution was added, and the mixture
was extracted three times with 10 mL of EtOAc. The com-
bined organic extracts were dried over sodium sulfate and
filtered. Evaporation of the solvent afforded 19 (17.6 mg,
0.04 mmol, 70%) as a brown solid which was used in the
next step without further purification. 1H NMR (300 MHz,
CDCl3): δ (ppm) = 8.17 (d, J = 1.9 Hz, 1H), 7.89
(d, J = 7.8 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 7.37 (dt, J = 9.1,
4.6 Hz, 1H), 7.34 to 7.14 (m, 3H), 7.09 to 6.99 (m, 1H), 6.94
(d, J = 2.2 Hz, 1H), 6.61 (dd, J = 8.4, 2.3 Hz, 1H),
4.19 (q, J = 7.2 Hz, 2H), 3.24 (t, J = 7.4 Hz, 2H), 2.86
(t, J = 7.4 Hz, 2H), 1.25 (t, J = 7.2 Hz, 3H); 13C NMR
(75 MHz, CDCl3): δ (ppm) = 178.2, 170.6, 169.2, 167.5,
157.9, 140.4, 137.2, 133.0, 132.7, 129.7, 125.7, 122.8, 122.7,
120.5, 120.4, 119.4, 118.6, 114.5, 112.7, 108.5, 108.4, 37.5, 32.6,
22.4, 13.6; MS (ESI+):m/z (%) = 528/526 (100/100) [M+Na]+.
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5-yl)-N-(9-ethyl-9H-carbazol-3-yl)propanamide (20)
To a solution of paraformaldehyde (PFA) (7.2 mg,
0.24 mmol, 6 eq.) in 90 μL of H2O, concentrated H2SO4
(13 μL, 0.24 mmol, 6 eq.) was added, and the reaction
was cooled in an ice bath. To the resulting solution, 19
(20 mg, 0.04 mmol, 1 eq.) in 1 mL THF was added, and
the reaction mixture was stirred for 30 min at 0°C. Next,
NaBH4 (granules, 9.1 mg, 0.24 mmol, 6 eq.) was added
in one portion, and the reaction was stirred for a further
18 h at rt. The reaction was quenched by addition of a
concentrated aqueous NaOH solution (pH = 10 to 12),
and the resulting aqueous phase was washed with EtOAc.
The organic phase was dried over sodium sulfate and
filtered. Upon purification by column chromatography
(silica, EtOAc/IH 3/7) a yellow-brown solid was obtained
which was further purified by recrystallization from THF
to give 20 as a colorless solid (11 mg, 0.12 mmol, 53%)
with mp = 125°C. 1H NMR (400 MHz, DMSO-d6): δ
(ppm) = 10.11 (s, 1H), 8.39 (s, 1H), 8.02 (d, J = 7.6 Hz,
1H), 7.66 (d, J = 8.9 Hz, 1H), 7.57 to 7.45 (m, 3H), 7.48 to
7.32 (m, 1H), 7.20 to 7.07 (m, 1H), 6.95 (d, J = 2.6 Hz,
1H), 6.77 (dd, J = 8.9, 2.6 Hz, 1H), 4.38 (q, J = 7.0 Hz, 2H),
3.28 (t, J = 7.0 Hz, 2H), 2.96 (t, J = 7.1 Hz, 2H), 2.95
(s, 6H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz,
DMSO-d6): δ (ppm) = 178.4, 168.6, 167.0, 156.7,
152.1, 139.9, 136.1, 132.2, 131.1, 125.7, 122.0, 121.8,
120.1, 118.8, 118.5, 116.0, 113.4, 111.1, 110.7, 109.1,





To a solution of dimethylamine 20 (53 mg, 0.1 mmol,
1 eq.) in 1 mL of dry DMF under argon, MeI (124 μL,
20 mmol, 20 eq.) was added at rt. The reaction was
sealed and warmed up to 35°C. Additional MeI (124 μL,
20 mmol, 20 eq.) was added after 2 and 5 days, while the
reaction temperature was maintained at 35°C. Upon solv-
ent evaporation, the resulting thick mass was washed three
times with 4 mL of EtOAc to remove trace impurities and
unreacted starting material (20). Upon drying, 4 mL of
H2O was added. The mixture was sonicated and
placed in a fridge (+4°C) for 1 h. The solid was
filtrated and rewashed with 4 mL of ice-cold H2O. The
trimethylammonium salt 13 was obtained as a light
brown solid (57 mg, 0.85 mmol, 85%) with mp = 109°C.
1H NMR (400 MHz,CD3CN): δ (ppm) = 8.71 (s, 1H), 8.41
(d, J = 1.9 Hz, 1H), 8.25 (d, J = 2.7 Hz, 1H), 8.08 (d, J = 7.8
Hz, 1H), 8.05 (d, J = 8.8 Hz, 1H), 7.93 (dd, J = 8.9, 2.8 Hz,
1H), 7.57 (dd, J = 8.7, 2.1 Hz, 1H), 7.49 (dt, J = 15.4, 8.2
Hz, 3H), 7.20 (ddd, J = 7.9, 6.9, 1.2 Hz, 1H), 4.40 (q, J = 7.2
Hz, 2H), 3.59 (s, 9H), 3.39 (t, J = 6.9 Hz, 2H), 3.05 (t, J =6.9 Hz, 2H), 1.37 (t, J = 7.2 Hz, 3H); 13C NMR (101 MHz,
CD3CN): δ (ppm) = 181.1, 169.8, 167.4, 149.2, 141.3,
137.7, 134.1, 131.7, 131.6, 127.5, 126.8, 123.9, 123.4, 121.2,
121.0, 120.0, 119.5, 112.6, 109.9, 109.8, 58.1 (3C), 38.2,
33.2, 22.9, 14.0; HRMS (ESI+): m/z (%) = 546.1531/
548.1436 (100/100) [M]+.
2-(9H-Carbazol-9-yl)ethanol (25)
Under N2, 9H-carbazole (23, 5.43 g, 32.5 mmol, 1.0 eq.)
was dissolved in THF (55 mL) and cooled down to −78°C.
n-Butyllithium (1.2 M in n-hexane, 32.4 mL, 38.9 mmol,
1.2 eq.) was added dropwise, and the mixture was stirred
for 30 min at −78°C. Then, a solution of ethylene sulfate
(4.51 g, 36.3 mmol, 1.1 eq.) in THF (15 mL) was added,
and the mixture was stirred for 1 h at −78°C and 24 h at
rt. H2O was added and the mixture was acidified to pH 1
with concentrated H2SO4and heated to reflux for 24 h.
Afterwards, the solution was neutralized with 5 M NaOH,
brine was added and the mixture was extracted with
CH2Cl2. The organic layers were dried (Na2SO4) and con-
centrated under reduced pressure, and the residue was
purified by fc (d = 8 cm, l = 12 cm, cyclohexane/EtOAc
65:35, Rf 0.42). Pale yellow solid, mp = 80°C, yield 4.66 g
(68%). Purity (HPLC): 98.1% (tR = 19.28 min).
1H NMR
(400 MHz, DMSO-d6): δ (ppm) = 3.86 (quart, J = 5.9 Hz,
2H), 4.47 (t, J = 5.5 Hz, 2H), 4.99 (t, J = 5.0 Hz, 1H), 7.24
(t, J = 7.4 Hz, 2H), 7.48 (t, J = 7.6 Hz, 2H), 8.18 (d, J = 7.8
Hz, 2H); 13C NMR (CDCl3): δ (ppm) = 45.3, 59.6, 109.6
(2C), 118.6 (2C), 120.2 (2C), 122.2 (2C), 125.0 (2C), 140.5
(2C); exact mass (APCI): m/z = calculated for C14H13NOH
212.1069, found 212.1060.
2-(3-Nitro-9H-carbazol-9-yl)ethanol (24)
9-(Hydroxyethyl)carbazole25 (5.11 g, 24.2 mmol, 1 eq.)
was dissolved in CH2Cl2 (100 mL) and cooled down to
5°C to10°C. Concentrated nitric acid (density 1.5 g/mL,
1.7 mL, 36.3 mmol, 1.5 eq.) was added dropwise under
vigorous stirring. Stirring was continued at <10°C until
the starting material was transformed completely. H2O
(25 mL) was added and the reaction mixture was neutral-
ized with NaHCO3. Subsequently, brine was added and
the mixture was extracted with CHCl3. The organic layer
was dried (Na2SO4) and concentrated under reduced
pressure; the residue was supported on silica and puri-
fied by fc (d = 8 cm, l = 12 cm, cyclohexane/EtOAc
50:50, Rf 0.27). Pale yellow solid, mp = 230°C, yield 3.34
g (54%). 1H NMR (CDCl3): δ (ppm) = 4.13 (t, J = 5.3 Hz,
2H), 4.55 (t, J = 5,3 Hz, 2H), 7.38 (t, J = 8.0 Hz, 1H), 7.51
to 7.60 (m, 3H), 8.13 (d, J = 7.5 Hz, 1H), 8.39 (dd, J = 8.9/
2.0 Hz, 1H), 9.03 (d, J = 2.2 Hz, 1H); 13C NMR (DMSO-
d6): δ (ppm) = 39.4, 59.6, 110.2, 110.9, 117.3 (2C), 120.7,
121.3, 122.0, 122.3, 127.4, 139.9, 141.8, 144.1; exact mass
(APCI): m/z = calculated for C14H12N2O3Na 279.0740,
found 279.0740.
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3-Nitro-9-(hydroxyethyl)carbazole (24, 500 mg, 1.95 mmol,
1.0 eq.) was dissolved in THF (10 mL/100 mg) and Pd/C
(100 mg) was added. The reaction mixture was stirred for
24 h at rt under H2 (balloon). The catalyst was removed by
filtration over Celite® and the filtrate was concentrated
under reduced pressure. The residue was dissolved in di-
ethyl ether. Under N2, HCl-Et2O (2 mol/L, 2 mL, 4 mmol,
2.0 eq.) was added drop wise under vigorous stirring to
produce the respective HCl salt. The precipitate was
filtered, washed with cold MeOH, and used without
further purification. Rf 0.35 (cyclohexane/ethyl acetate
30:70). Colorless solid with mp = 230°C, yield 492 mg
(96%). 1H NMR (26-HCl, DMSO-d6): δ (ppm) = 3.78
(t, J = 5.5 Hz, 2H), 4.47 (t, J = 5.5 Hz, 2H), 7.24 (t, J = 7.4 Hz,
1H), 7.45 (dd, J = 8.7/2.1 Hz, 1H), 7.50 (t, J = 7,7 Hz, 1H),
7.66 (d, J = 8.3 Hz, 1H), 7.74 (d, J = 8.7 Hz, 1H), 8.12 (d,
J = 2.1 Hz, 1H), 8.18 (d, J = 7.7 Hz, 1H), 10.4 (s, 3H);
13C NMR (26-HCl, DMSO-d6): δ (ppm) = 45.5, 59.7,
110.2, 110.8, 114.8, 119.3, 120.6, 121.5, 122.3, 122.8, 126.7
(2C), 139.7, 141.2; exact mass (APCI): m/z = calculated for
C14H15N2O 217.1179, found 217.1179.3-[3-(2-Bromo-4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-N-
[9-(2-hydroxyethyl)-9H-carbazol-3-yl]propanamide (14)
Compound 10 (400 mg, 1.3 mmol 1 eq.) was treated with
COMU® (652 mg, 1.5 mmol 1.2 eq.) and triethylamine
(0.54 mL, 3.9 mmol, 3.3 eq.) in DMF (15 mL) for 30 min
at rt. The reaction mixture was cooled down to 0°C, and
a solution of the 3-aminocarbazole hydrochloride 26
(222 mg, 0.9 mmol, 1.0 eq.) in DMF was added dropwise.
The mixture was stirred for 24 h at <10°C. Then, H2O and
brine were added, the mixture was extracted with CHCl3,
the combined organic layers were dried (Na2SO4) and
concentrated in vacuo, and the residue was purified by fc
(d = 5 cm, l = 15 cm, cyclohexane/EtOAc 15:85, Rf 0.51
(EtOAc)). Colorless solid, mp = 164°C, yield 368 mg
(80%). Purity (HPLC), 97.7% (tR = 20.24 min).
1H NMR
(DMSO-d6): δ (ppm) = 2.99 (t, J = 7.0 Hz, 2H), 3.35 (t,
J = 7.1 Hz, 2H), 3.76 (q, J = 5.6 Hz, 2H), 4.40 (t, J = 5.5
Hz, 2H), 4.86 (t, J = 5.4 Hz, 1H), 7.15 (t, J = 7.4 Hz,
1H), 7.41 (t, J = 6.5 Hz, 1H), 7.46 (td, J = 8.5/2.6 Hz,
1H), 7.51 (dd, J = 8.8/1.7 Hz, 1H), 7.54 (d, J = 8.8
Hz, 1H,), 7.57 (d, J = 8.3 Hz, 1H), 7.83 (dd, J =
8.6/2.6 Hz, 1H), 7.89 (dd, J = 8.7/6.1 Hz, 1H), 8.02 (d,
J = 7.8 Hz, 1H), 8.39 (s, 1H), 10.13 (s, 1H); 13C NMR
(DMSO-d6): δ (ppm) = 21, 32.0, 45.3, 59.6, 109.5,
109.7, 110.9, 115.5 (d, J = 21.6 Hz,1C), 118.5, 118.7,
120.0, 121.4 (d, J = 24.9 Hz, 1C), 121.7, 122.0, 122.2
(d, J = 10.1 Hz, 1C), 124.5 (d, J = 3.4 Hz,1C), 125.6, 131.0,
133.6 (d, J = 9.3 Hz, 1C), 137.0, 140.9, 162.9 (d, J = 253.4
Hz, 1C), 166.4, 168.5, 179.6; exact mass (ESI): m/z = calcu-
lated for C25H20
79BrFN4O3H 523.0776, found 523.0783.3-[3-(2-Bromo-4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-N-
(9-ethyl-9H-carbazol-3-yl)propanamide (2)
The synthesis of 2 is described in [29].
3-[3-(2-Bromo-4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-N-
[9-(2-fluoroethyl)-9H-carbazol-3-yl]propanamide (1)
Under N2, XtalFluor-E® (263 mg, 1.2 mmol, 1.5 eq.) was
suspended in CH2Cl2 (15 mL). Triethylamine trihydro-
fluoride (NEt3-3HF) (0.2 mL, 1.2 mmol, 1.5 eq.) and a so-
lution of 14 (400 mg, 0.8 mmol, 1 eq.) in CH2Cl2 (20 mL)
were added to the suspension via cannula at −78°C. The
resulting mixture was warmed up to rt within 3 h. An
aqueous solution of Na2CO3 (5% m/m) was added, and
the reaction mixture was stirred for 15 min at rt. After the
addition of brine, the mixture was extracted with CH2Cl2,
the organic layer was dried (Na2SO4) and concentrated
in vacuo, and the residue was purified by fc (d = 6 cm,
l = 15 cm, cyclohexane/EtOAc 20:80, Rf = 0.53 (EtOAc)).
The product (1) was recrystallized from ethyl acetate
yielding 82 mg of colorless solid (yield 20%) with mp of
201°C. Purity (HPLC), 96.7% (tR = 21.46 min).
1H NMR
(CDCl3): δ (ppm) = 2.97 (t, J = 7.0 Hz, 2H), 3.39 (t, J =
7.0 Hz, 2H), 4.51 (dt, J = 24.2/5.1 Hz, 2H), 4.72 (dt, J =
46.8/5.1 Hz, 2H), 7.03 to 7.09 (m, 1H), 7.16 (t, J = 7.0 Hz,
1H), 7.27 (d, J = 8.6 Hz, 1H), 7.32 (d, J = 8.2 Hz, 2H), 7.36
to 7.43 (m, 3H), 7.56 (s, 1H), 7.76 (dd, J = 8.7/6.0 Hz, 1H),
7.97 (d, J = 7.8 Hz, 1H), 8.41 (d, J = 1.8 Hz); 13C NMR
(DMSO-d6): δ (ppm) = 21.8, 32.0, 42.9 (d, J = 19.7 Hz),
82.6 (d, J = 167.9 Hz), 109.5, 109.6, 110.9, 115.5 (d, J =
21.7 Hz), 118.8, 118.9, 120.0, 121.4 (d, J = 25.1 Hz), 121.9,
122.1, 122.2 (d, J = 9.9 Hz), 124.5 (d, J = 3.4 Hz), 125.8,
131.4, 133.6 (d, J = 9.3 Hz), 136.7, 140.6, 162.9 (d, J =
253.2 Hz), 166.4, 168.5, 179.6; HRMS (APCI):m/z = calcu-
lated for C25H19




Under N2, compound 14 (250 mg, 0.5 mmol, 1 eq.), 4-
dimethylaminopyridine (17.5 mg, 0.15 mmol, 0.3 eq.),
and triethylamine (0.25 mL, 1.8 mmol, 3.6 eq.) were
dissolved in THF (20 mL) and cooled down to 0°C. A
solution of p-toluenesulfonyl chloride (183 mg, 1.0
mmol, 2 eq.) in THF (10 mL) was added dropwise. After
20 min, the mixture was warmed up to rt and stirred for
48 h. Subsequently, 1 M aq. NaOH (3 mL) was added
and the layers were separated. The aqueous layer was
extracted with CH2Cl2 and the organic layer was
washed with brine. The combined organic layers were
dried (Na2SO4) and concentrated in vacuo, and the resi-
due was purified by fc (d = 5 cm, l = 10 cm, cyclohexane/
EtOAc 40:60, Rf = 0.34 (cyclohexane/EtOAc 50:50)). The
product (15) was recrystallized from CH2Cl2 yielding
197 mg (colorless solid, mp = 136°C, yield 61%). Purity
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1H NMR (CDCl3):
δ (ppm) = 2.24 (s, 3H), 3.04 (t, J = 7.0 Hz, 2H), 3.47
(t, J = 7.0 Hz, 2H), 4.38 (t, J = 5.4 Hz, 2H), 4.49
(t, J = 5.3 Hz, 2H), 6.85 (d, J = 8.0 Hz, 2H), 7.15 (t, J = 7.4
Hz, 1H), 7.17 to 7.23 (m, 5H), 7.33 (dd, J = 8.7/1.9 Hz, 1H),
7.39 (t, J = 8.1 Hz, 1H), 7.46 (dd, J = 8.2/2.4 Hz, 1H), 7.74
(s, 1H), 7.83 (dd, J = 8.7/6.0 Hz, 1H), 7.94 (d, J = 7.8 Hz,
1H), 8.31 (d, J = 1.7 Hz, 1H); 13C NMR (DMSO-d6): δ
(ppm) = 21.0, 21.8, 32.0, 41.3, 68.8, 109.2, 109.3, 110.8,
115.5 (d, J = 21.1 Hz, 1C), 118.5, 118.8, 119.9, 121.4 (d, J =
24.9 Hz, 1C), 122.0, 122.1 (d, J = 9.9 Hz, 1C), 122.2, 124.5
(d, J = 3.3 Hz, 1C), 125.7, 126.6 (2C), 129.5 (2C), 131.0,
131.3, 133.6 (d, J = 9.2 Hz, 1C), 136.3, 140.3, 144.4,
162.9 (d, J = 253.5 Hz, 1C), 166.6, 168.5, 179.7; HRMS




At −10°C, SOCl2 (71 μL, 0.77 mmol, 3.3 eq.) was dissolved
in 0.5 mL MeOH and stirred for 10 min. Acid 9 (100 mg,
0.29 mmol, 1 eq.) was then added and the reaction was
allowed to reach room temperature within 1 h. The reac-
tion was stirred further for 1 h at rt and quenched by the
addition of 5 mL saturated aq. NaHCO3 solution, and
the product was extracted with EtOAc (three times with
5 mL). Evaporation of the solvent afforded 21 in a quan-
titative manner (104 mg, 0.29 mmol). 1H NMR (400 MHz,
CDCl3): δ (ppm) = 8.59 (d, J = 2.2 Hz, 1H), 8.26
(dd, J = 8.6, 2.2 Hz, 1H), 8.06 (d, J = 8.6 Hz, 1H),
3.73 (s, 3H), 3.32 (t, J = 7.2 Hz, 2H), 2.97 (t, J = 7.2 Hz,
2H); 13C NMR (100 MHz, CDCl3): δ (ppm) = 178.8, 171.6,
166.7, 149.0, 134.1, 132.8, 129.4, 122.8, 122.2, 52.3, 30.2,
22.1; MS (ESI+): m/z (%) = 356/358 (100/100) [M+H]+.Methyl-3-(3-(4-amino-2-bromophenyl)-1,2,4-oxadiazol-5-yl)
propanoate (16)
To a solution of 21 (50 mg, 0.13 mmol, 1 eq.) in 2 mL
EtOH, SnCl2-2H2O (149 mg, 0.66 mmol, 5 eq.) was
added and the reaction was stirred for 2 h at rt. Satu-
rated aq. NaHCO3 solution (5 mL) was added, and the
mixture was extracted with EtOAc. The organic phase
was dried over sodium sulfate and filtered. Upon solv-
ent evaporation under reduced pressure, amine 16 was
obtained as a brown solid (45 mg, 0.13 mmol, quant).
1H NMR (400 MHz, DMSO-d6): δ (ppm) = 7.45 (d, J =
8.5 Hz, 1H), 6.92 (d, J = 2.2 Hz, 1H), 6.64 (dd, J = 8.5,
2.2 Hz, 1H), 3.55 (s, 4H), 3.13 (dd, J = 7.6, 5.9 Hz, 2H),
2.93 – 2.74 (m, 2H); 13C NMR (100 MHz, DMSO-d6):
δ (ppm) = 178.6, 172.8, 167.7, 152.5, 133.2, 122.4, 118.7,
114.1, 113.6, 52.4, 30.2, 22.0; MS (ESI+): m/z (%) = 348/
350 (100/100) [M+Na]+.Methyl-3-(3-(2-bromo-4-(dimethylamino)phenyl)-1,2,4-
oxadiazol-5-yl)propanoate (22)
Compound 22 was synthesized as described for 20 from
16 in 52% yield as a brown solid. 1H NMR (300 MHz,
CDCl3): δ (ppm) = 7.75 (d, J = 8.8 Hz, 1H), 7.00 (d, J =
2.6 Hz, 1H), 6.70 (dd, J = 8.9, 2.6 Hz, 1H), 3.72 (s, 3H),
3.25 (t, J = 7.4 Hz, 2H), 3.01 (s, 6H), 2.93 (t, J = 7.4 Hz,
2H); 13C NMR (75 MHz, CDCl3): δ (ppm) = 177.2,
171.9, 168.0, 152.0, 132.7, 123.1, 117.2, 115.2, 111.0, 52.3




Compound 18 was synthesized as described for 13 from
22 in 90% yield as a brown solid (mp = 119°C). 1H NMR
(300 MHz, CD3CN): δ (ppm) = 8.29 (d, J = 2.6 Hz, 1H),
8.04 (d, J = 8.8 Hz, 1H), 7.98 (dd, J = 8.9, 2.7 Hz, 1H),
3.68 (s, 3H), 3.63 (s, 9H), 3.29 (t, J = 6.9 Hz, 2H), 2.94
(t, J = 6.9 Hz, 2H); 13C NMR (75 MHz, CD3CN): δ (ppm) =
181.1, 173.4, 168.0, 134.7, 132.1, 128.2, 124.4, 121.8,
118.8, 58.8 (3C), 53.1, 31.3, 23.3; HRMS (ESI+): m/z
(%) = 368.0616/370.0615 (100/100) [M]+.
Methyl-3-(3-(2-bromo-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)
propanoate (17)
Compound 17 was synthesized as described for 21 from
10 in a quantitative manner as a colorless solid (mp =
39°C). 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.84 (dd,
J = 8.7, 6.0 Hz, 1H), 7.47 (dd, J = 8.3, 2.5 Hz, 1H), 7.14
(ddd, J = 8.7, 7.7, 2.6 Hz, 1H), 3.73 (s, 3H), 3.29 (t, J =
7.3 Hz, 2H), 2.94 (t, J = 7.3 Hz, 2H); 13C NMR (100
MHz, CDCl3): δ (ppm) = 178.1, 171.7, 167.3, 164.7,
162.2, 133.4 (d, J = 9.1 Hz), 122.9 (d, J = 9.9 Hz), 121.7
(d, J = 24.7 Hz), 115.0 (d, J = 21.4 Hz), 52.2, 30.3, 22.1;
19 F NMR (376 MHz, CDCl3): δ (ppm) = −108.0 (dd, J =
14.1, 7.9 Hz); MS (ESI+): m/z (%) = 351/353 (100/100)
[M+Na]+.
Radiochemistry
No-carrier-added [18F]fluoride (t1/2 = 109.8 min) was pro-
duced via the [18O(p,n)18F] nuclear reaction by irradiation
of a [18O]H2O target (Hyox 18 enriched water, Rotem In-
dustries Ltd, Israel) on a Cyclone®18/9 (iba RadioPharma
Solutions, Belgium) with a fixed energy proton beam using
Nirta® [18F]fluoride XL target. Aqueous [18F]fluoride was
dried by azeotropic distillation using MeCN in the pres-
ence of K2CO3 (1.78 mg, 12.9 mmol) and Kryptofix 2.2.2
(K2.2.2, 11.2 mg, 29.7 mmol), resulting in the reactive an-
hydrous K[18F]F-K2.2.2-carbonate complex. Optimization
of the aliphatic and aromatic radiolabellings of tosylate
15 and trimethylammonium salt 13, respectively, were
performed by varying the amount of precursor for
radiolabelling and reaction time under thermal heating
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tions, the reaction mixtures of [18F]1 and [18F]2 were
diluted with water and directly applied to an isocratic
semi-preparative RP-HPLC for isolation of the desired
radiotracers (see ‘Experimental’ section). The collected
fractions were analyzed by radio-TLC, and those with
the highest radiochemical purity were combined, di-
luted with water, passed through a Sep-Pak C18 light
cartridge (Waters, Milford, MA, USA), and eluted with
0.6 mL of diethyl ether (DEE). The elution of [18F]1 and
[18F]2 was performed in polypropylene vials containing
75 to 100 μL of EtOH. For biological investigations, the
solvent was evaporated to dryness under a gentle argon
stream, and the desired radiotracers were formulated in
a sterile isotonic solution containing 10% EtOH (v/v).
The identities of [18F]1 and [18F]2 were verified by
radio-HPLC of samples of the respective radiotracer
spiked with the non-radioactive reference compound.
Radiochemical and chemical purities were assessed by
radio-TLC and analytical HPLC. Specific activities were
calculated using the HPLC method described in [43].
For evaluation of radiometabolites, the radiosynthesis of
the trimethylammonium salt 18 to afford [18F]17 was
performed following the same conditions as above
stated for [18F]1 and [18F]2 (Scheme 5).
Determination of lipophilicity (logD) and stability
The distribution coefficients of [18F]1 and [18F]2 were
also calculated from RP-HPLC retention times in three
different systems: (1) isocratic elution (60% MeCN/20
mM NH4OAc at a flow rate of 1 mL/min) and (2) gradi-
ent elution (starting from 10% MeCN/20 mM NH4OAc
aq. for 10 min with a gradient to 90% MeCN/20 mM
NH4OAc aq. over 30 min at a flow rate of 1 mL/min) on
a Reprosil-Pur C18-AQ column (5 μm, 250 × 4.6 mm,
Dr. Maisch HPLC GmbH, Ammerbruch-Entringen,
Germany), and (3) isocratic elution (52.5% MeCN/20 mM
NH4OAc at a flow rate of 1 mL/min) on a Prodigy 5 μm
C8 (250 × 4 mm; Phenomenex Ltd, Aschaffenburg,
Germany) using the reference compounds following
the protocol according to the EU guideline 67/548/
EWG [44].
In vitro radiochemical stabilities of [18F]1 and [18F]2
were investigated in 0.9% NaCl solution, Dulbecco’s
phosphate buffer, 0.01 M Tris–HCl (pH 7.4 at 21°C),
and EtOH at 40°C for 90 min. Samples were taken at 15,
30, 60, and 90 min after incubation and analyzed by
radio-TLC and radio-HPLC.
In vitro CB receptor affinity assay
For binding experiments, Chinese hamster ovary (CHO)
cell lines stably transfected with human CB1R human
and CB2R were used according to the procedures previ-
ously described [29]. Briefly, displacement of CB1R/CB2R-specific radioligand [
3H]CP55,940 (6,438 GBq/
mmol; PerkinElmer Life and Analytical Sciences GmbH,
Rodgau, Germany; working concentration, 0.2 to 0.5 nM)
by test compounds in the range of 0.1 nM to 10 μ was
assessed, and IC50 values were estimated by non-linear
regression (GraphPad Prism; version 3.0, GraphPad
Software, Inc., San Diego, CA, USA). KD values of 2.4
and 1.5 nM were previously determined for [3H]CP55,940
binding to hCB1R and hCB2R, respectively, and used for
calculation of Ki values of the test compounds according
to Cheng et al. [45]. The binding experiments were
performed in triplicates, and data were given as mean
values from independent experiments.
Ex vivo biodistribution studies
Animals for in vivo studies were obtained from the
Medizinisch-Experimentelles Zentrum, Universität Leipzig.
All procedures that include animals were approved by
the respective State Animal Care and Use Committee
and conducted in accordance with the German Law for
the Protection of Animal.
Female CD1 mice (10 to 12 weeks old, 20 to 25 g)
received an injection of 300 to 400 kBq of [18F]1 or [18F]2
with specific activities of >450 GBq/μmol in 200 μL of
0.9% NaCl/10% EtOH into the tail vein. The animals
were anesthetized (CO2/O2 mixture) for blood and urine
sampling and euthanized by luxation of the cervical spine
at 5, 30, and 60 min after injection (p.i.) (n = 2 to 5 per
time). The organs of interest were removed and weighed,
and the activities were measured by γ counting using a
calibrated γ counter Wallac Wizard 1470 (Perkin Elmer
Inc., Waltham, MA, USA). The percentage of injected
dose per gram of wet tissue (% ID/g wet weight) was
calculated.
To verify the specificity of [18F]1 and [18F]2 towards
CB2R, blocking experiments were performed with pre-
administration of the highly selective CB2R inverse agonist
SR144528 [46] (3 mg/kg i.p. in 0.9% saline, 10 min before
the injection of the radiotracer) at 60 min p.i. (n = 2 to 5).
The unpaired two-tailed t test was used to compare the
results between the groups. We considered differences
to be significant at a p value <0.05.
Ex vivo metabolite studies
[18F]1 and [18F]2 (100 to 150 MBq, 250 to 450 GBq/μmol
in 150 μL NaCl 0.9%/10% EtOH) were injected via the tail
vein in CD1 male mice (10 to 12 weeks old, 20 to 25 g).
Blood and urine samples were obtained at 30 and 60 min
p.i. (n = 3 per time point). Twofold extractions of plasma
and brain samples (n = 3) were performed using ice-cold
MeCN according to the standard protocol established in
our group (see [47,48]). Briefly, plasma samples were
obtained by centrifugation of the blood at 4,000×g at
4°C for 10 min, and brain samples were homogenized
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were vortexed, incubated on ice, and centrifuged at
10,000×g for 3 min. Supernatants were collected, and
the precipitates were re-dissolved in ice-cold MeCN
for the second extraction. The supernatants from the two
extractions were combined, concentrated under a gentle
argon stream at 65°C, and analyzed by radio-TLC and
gradient analytical HPLC (see ‘Radiochemistry’ section).
Aliquots from each extraction supernatant and the pre-
cipitates were also taken and quantified by γ counting
(Wallac Wizard 1470, Perkin Elmer Inc., Waltham, MA,
USA) along with the respective aliquots of intact plasma
samples and brain homogenates. A moderate recovery
of radioactivity was obtained from plasma samples and
brain homogenates (60% to 70%). Radiometabolites of
[18F]17 in the plasma, spleen, and brain were assessed
at 30 and 60 min p.i.Conclusions
In conclusion, N-aryl-oxadiazolyl-propionamides were
successfully radiolabelled with 18F at different posi-
tions. Fluorine substitution at these positions did not
affect affinity and specificity towards CB2R. However,
the radiotracers investigated in this study undergo a
fast metabolism in vivo with the main radiometabolites
crossing the blood–brain barrier. Therefore, structural
changes in the enzymatic cleavage sites of the evalu-
ated candidates have to be performed to enhance their
potential as CB2R PET imaging agents for the brain.Additional file
Additional file 1: Supplemental information. In the additional file,
data of the blocking studies (% blocking, p values) are compiled.Abbreviations
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